[1] World Health Organization. Cancer fact sheet. Updated March2021. [2021-06-07]. https://gco.iarc.fr/today
[2] Moynihan K D, Irvine D J. Roles for innate immunity in combination immunotherapies. Cancer Research, 2017, 77: 5215-5221
[3] Gasteiger G, Fan X, Dikiy S, et al. Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs. Science, 2015, 350: 981-985
[4] Lugini L, Cecchetti S, Huber V, et al. Immune surveillance properties of human NK cell-derived exosomes. The Journal of Immunology, 2012, 189: 2833-2842
[5] Vivier E, Raulet D H, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science, 2011, 331: 44-49
[6] Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene, 2008, 27: 5932-5943
[7] Gorre M E, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001, 293: 876-880
[8] Gerlinger M, Swanton C. How darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. British Journal of Cancer, 2010, 103: 1139-1143
[9] Meacham C E, Morrison S J. Tumour heterogeneity and cancer cell plasticity. Nature, 2013, 501: 328-337
[10] Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers, 2014, 6: 1769-1792
[11] Tian T, Olson S, Whiteacre J M, Harding A. The origins of cancer robustness and evolvability. Integrative Biology, 2011, 3: 17-30
[12] Saunders N A, Simpson F, Thompson E W, et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Molecular Medicine, 2012, 4: 675-684
[13] Kumar N, Cramer G M, Dahaj S A Z, et al. Stochastic modeling of phenotypic switching and chemoresistance in cancer cell populations. Scientific Reports, 2019, 9: 10845
[14] Sun X, Zhang J, Zhao Q, et al. Stochastic modeling suggests that noise reduces differentiation efficiency by inducing a heterogeneous drug response in glioma differentiation therapy. BMC Systems Biology, 2016, 10: Art 73
[15] Hodgkinson A, Cam L L, Trucu D, et al. Spatio-Genetic and phenotypic modelling elucidates resistance and re-sensitisation to treatment in heterogeneous melanoma. Journal of Theoretical Biology, 2019, 466: 84-105
[16] Sudalagunta P, Silva M C, Canevarolo R R, et al. A pharmacodynamic model of clinical synergy in multiple myeloma. EBioMedicine, 2020, 54: 102716
[17] Wang Z, Butner J D, Cristini V, et al. Integrated PK-PD and agent-based modeling in oncology. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42: 179-189
[18] Osojnik A, Gaffney E A, Davies M, et al. Identifying and characterising the impact of excitability in a mathematical model of tumour-immune interactions. Journal of Theoretical Biology, 2020, 501: 110250
[19] Pang L, Liu S, Zhang X, et al. Mathematical modeling and dynamic analysis of anti-tumor immune response. Journal of Applied Mathematics and Computing, 2020, 62: 473-488
[20] Kogan Y, Halevi-Tobias K, Elishmereni M, et al. Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization. Cancer Research, 2012, 72: 2218-2227
[21] Ghaffari A, Naserifar N. Optimal therapeutic protocols in cancer immunotherapy. Computers in Biology and Medicine, 2010, 40: 261-270
[22] Ledzewicz U, Naghnaeian M, Schättler H. Optimal response to chemotherapy for a mathematical model of tumor-immune dynamics. Journal of Mathematical Biology, 2012, 64: 557-577
[23] Butner J D, Dogra P, Chung C, et al. Mathematical modeling of cancer immunotherapy for personalized clinical translation. Nature Computational Science, 2022, 2: 785-796
[24] Sun X, Hu B. Mathematical modeling and computational prediction of cancer drug resistance. Briefings in Bioinformatics, 2018, 19: 1382-1399
[25] Wilkie K P. A review of mathematical models of cancer-immune interactions in the context of tumor dormancy. Systems Biology of Tumor Dormancy, 2013, 734: 201-234
[26] Mahlbacher G, Curtis L T, Lowengrub J, et al. Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment. Journal for Immunotherapy of Cancer, 2018, 6: Art 10
[27] Hoffman F, Gavaghan D, Osborne J, et al. A mathematical model of antibody-dependent cellular cytotoxicity (ADCC). Journal of Theoretical Biology, 2018, 436: 39-50
[28] Serre R, Benzekry S, Padovani L, et al. Mathematical modeling of cancer immunotherapy and its synergy with radiotherapy. Cancer Research, 2016, 76: 4931-4940
[29] Rozova V, Bratus A. Therapy strategy in tumour cells and immune system interaction mathematical model. Applicable Analysis, 2016, 95: 1548-1559
[30] Mahasa K J, Ouifki R, Eladdadi A, et al. Mathematical model of tumor-immune surveillance. Journal of Theoretical Biology, 2016, 404: 312-330
[31] Song G, Tian T, Zhang X. A mathematical model of cell-mediated immune response to tumor. Mathematical Biosciences and Engineering, 2020, 18: 373-385
[32] Macfarlane F R, Lorenzi T, Chaplain M A J. Modelling the immune response to cancer: an individual-based approach accounting for the difference in movement between inactive and activated T cells. Bulletin of Mathematical Biology, 2018, 80: 1539-1562
[33] Mahlbachera G E, Reihmera K C, Frieboesa H B. Mathematical modeling of tumor-immune cell interactions. Journal of Theoretical Biology, 2019, 469: 47-60
[34] Sun X, Bao J, Shao Y. Mathematical modeling of therapy-induced cancer drug resistance: connecting cancer mechanisms to population survival rates. Scientific Reports, 2016, 6: 22498
[35] Komarova N, Wodarz D. Drug resistance in cancer: Principles of emergence and prevention. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102: 9714-9719
[36] Iwasa Y, Nowak M A, Michor F. Evolution of resistance during clonal expansion. Genetics, 2006, 172: 2557-2566
[37] Tomasetti C, Levy D. An elementary approach to modeling drug resistance in cancer. Mathematical Biosciences and Engineering, 2010, 7: 905-918
[38] Chisholm R H, Lorenzi T, Clairambault J. Cell population heterogeneity and evolution towards drug resistance in cancer: biological and mathematical assessment, theoretical treatment optimisation. Biochimica et Biophysica Acta (BBA)-General Subjects, 2016, 1860: 2627-2645
[39] De Pillis L G, Radunskaya A. A mathematical tumor model with immune resistance and drug therapy: an optimal control approach. Computational and Mathematical Methods in Medicine, 2001, 3: 79-100
[40] Tran A P, Ali Al-Radhawi M, Kareva I, et al. Delicate balances in cancer chemotherapy: Modeling immune recruitment and emergence of systemic drug resistance. Frontiers in Immunology, 2020, 11: 1376
[41] Piretto E, Delitala M, Ferraro M. Combination therapies and intra-tumoral competition: insights from mathematical modeling. Journal of Theoretical Biology, 2018, 446: 149-159
[42] Barish S, Ochs M F, Sontag E D, et al. Evaluating optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy. Proceedings of the National Academy of Sciences, 2017, 114: E6277-E6286
[43] Angelini E, Wang Y, Zhou J X, et al. A model for the intrinsic limit of cancer therapy: Duality of treatment-induced cell death and treatment-induced stemness. PLOS Computational Biology, 2022, 18: e1010319
[44] Masud M A, Kim J Y, Kim E. Effective dose window for containing tumor burden under tolerable level. NPJ Systems Biology and Applications, 2023, 9: Art 17
[45] Kuznetsov V A, Makalkin I A, Taylor M A, et al. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bulletin of Mathematical Biology, 1994, 56: 295-321
[46] Diefenbach A, Jensen E, Jamieson A, et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumor immunity. Nature, 2001, 413: 165-171
[47] Wilkie K P, Hahnfeldt P. Mathematical models of immune-induced cancer dormancy and the emergence of immune evasion. Interface Focus, 2013, 3: 20130010
[48] Yates A, Callard R. Cell death and the maintenance of immunological memory. Discrete and Continuous Dynamical Systems-B, 2001, 1: 43-59
[49] Kiran K L, Lakshminarayanan S. Optimization of chemotherapy and immunotherapy: in silico analysis using pharmacokinetic-pharmacodynamic and tumor growth models. Journal of Process Control, 2013, 23: 396-403
[50] Guckenheimer J, Holmes P. Nonlinear Oscillation, Dynamical Systems and Bifurcation of Vector Fields. Berlin: Springer-Verlag, 1983
[51] Kuang Y, Takeuchi Y. Predator-prey dynamic in models of prey dispersal in two patch environments. Mathematical Biosciences, 1994, 120: 77-98
[52] Narendra B L, Reddy K E, Shantikumar S, et al. Immune system: a double-edged sword in cancer. Inflammation Research, 2013, 62: 823-834
